Gregor Awang, Director, Biologics Process Development
24+ years of experience developing upstream and recombinant-protein downstream processes and tech transferring these processes from lab to manufacturing scale
Past roles with: Cangene Corporation, Emergent BioSolutions
PhD, Industrial Microbiology from University of Saskatchewan, M.Sc. Environmental Microbiology from University of Manitoba
Joined BIOVECTRA in 2019
John Riley - Director, Process Development and Technical Support Chemistry
Obtained a B.Sc. for Biology and Chemistry from the University of New Brunswick in 1998.
Obtained a Ph.D. in Chemistry, with a specialization in Organic Chemistry, from Dalhousie University in 2003.
Served as a post-doctoral fellow at the University of South Florida in 2003, and Queen’s University from 2003-2005.
Joined BIOVECTRA Inc. in 2006 as a Research Scientist.
Promoted to Senior Scientist in 2012.
Worked extensively on the synthesis of functionalized polyethylene glycol polymers for use in protein conjugate therapeutics.
The author of two patents in the areas of Polyethylene glycol purification, and small molecule formulation.
In 2018, became the Director, Process Development and Technical Support Chemistry.
Krista Affleck - Director, Analytical Development
Master of Science degree from the University of Prince Edward Island (2002).
Hired by BIOVECTRA as a Quality Control Chemist (2002).
Joined R&D group as Research Technician in 2003.
Joined Analytical Chemistry group in 2008.
Promoted to Group Leader on the Analytical Chemistry group in 2012.
In 2014, became the Manager, Analytical Support, and Development in the R&D group.
In 2018, became the Director, Analytical Development.
Ankur Deshpande – Director, Process Development Quality
M.Sc. in Organic Chemistry from The University of New Brunswick (2008)
Has 12 years of experience in the pharmaceutical industry in analytical services and quality
Joined BIOVECTRA in 2010 as a QC Chemist
Clement Mugabe, Ph.D. – Program Manager, Process Development
Ph.D. degree in Pharmaceutical Sciences from the University of British Columbia in 2011
10+ years of experience in drug formulation and pre-formulation
Post-doctoral work at the Centre for Drug Research and Development (CDRD) where he was awarded the Merck/Michael Smith Foundation Post-Doctoral Fellowship in Drug Delivery
During his PhD, Clement developed a novel nanoparticulate formulation of paclitaxel and docetaxel based on hyperbranched polyglycerols for application in bladder cancer therapy
15+ peer-reviewed scientific articles and contributed to 2 book chapters and patent applications in the area of nanomedicine and drug delivery
Joined BIOVECTRA in 2016
Oliver Technow - Chief Executive Officer
Industry Master Degree from Frankfurt Chamber of Commerce, Frankfurt Germany.
More than 20 years of global pharmaceutical industry experience.
Held numerous leadership positions in commercial development, marketing and brand management, and lifecycle management and has extensive product launch and market access expertise in Europe and North America.
In 1997, joined Eisai GmbH in Frankfurt, Germany and in 2002, was appointed Director, CNS Business Unit; in 2006, was appointed Vice President, Head of Global Marketing for Eisai Inc. in Woodcliff Lake, NJ; in 2011, was appointed Vice President, Established Products Business Unit; in 2013, was appointed President & General Manager for Eisai Limited in Mississauga, ON.
Appointed President of BIOVECTRA Inc., December 10, 2015.
Board Director for BIOTECanada
Member of the Steering Council of Innovative Medicines Canada (IMC)
In 2017, appointed to the Government of Canada’s Health/Bio-sciences Strategic Economic Table
In November 2019, promoted to Chief Executive Officer at BIOVECTRA
In June 2020, named new Chair of PEI BioAlliance Board of Directors